Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

42.8K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
42.8K
Standard Precaution01:26

Standard Precaution

3.2K
Standard precautions are the minimum infection control safeguards used while caring for all patients, irrespective of their disease condition. They help prevent the spread of common infectious microorganisms to healthcare workers, patients, and visitors in all healthcare settings.
Hand hygiene is the most crucial means to prevent the transmission of disease. Employers are legally required to provide their workers with personal protective equipment (PPE) to minimize exposure or contact with...
3.2K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.7K
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

2.0K
Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
2.0K
Transmission-based Precautions I: Contact, Enteric, and Droplets01:17

Transmission-based Precautions I: Contact, Enteric, and Droplets

5.0K
Transmission-based precautions are for patients known to be infected or suspected to be infected or colonized with organisms that pose a significant risk to others. Some transmission-based precautions include contact, enteric, and droplet.
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges. Reply.

The New England journal of medicine·2026
Same author

Prospective HIV RNA screening with long-acting cabotegravir pre-exposure prophylaxis in HPTN 083.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Rapid diagnostic tests, laboratory-based immunoassay and nucleic acid testing strategies for long-acting injectable pre-exposure prophylaxis: A systematic review and meta-analysis.

PLoS medicine·2026
Same author

Providing the Best Infectious Diseases and Primary Care to Our Patients With HIV: Time for Delivery Models to Evolve.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Protecting preexposure prophylaxis: the perils of laboratory testing ignored.

AIDS (London, England)·2026
Same journal

Expert consensus on case definitions in human loiasis: a Delphi study.

The Lancet. Infectious diseases·2026
Same journal

The Bundibugyo virus disease outbreak: a warning signal for risks to health workers.

The Lancet. Infectious diseases·2026
Same journal

Trials of medical countermeasures to begin in DR Congo.

The Lancet. Infectious diseases·2026
Same journal

Community-based tuberculosis screening with computer-aided detection technology alone and in combination with point-of-care C-reactive protein testing: a paired screen-positive trial.

The Lancet. Infectious diseases·2026
Same journal

Context matters: WHO-recommended tools in combinations validated for community tuberculosis screening.

The Lancet. Infectious diseases·2026
Same journal

Global, regional, and national burden of tuberculosis and multidrug-resistant tuberculosis by HIV status, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.

The Lancet. Infectious diseases·2026
See all related articles

Related Experiment Video

Updated: Apr 26, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

19.2K

Moving HIV PrEP from research into practice

Raphael J Landovitz1, Thomas J Coates2

  • 1UCLA Center for Clinical AIDS Research and Education, Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA 90049, USA.

The Lancet. Infectious Diseases
|July 29, 2014
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Amplification of Near Full-length HIV-1 Proviruses for Next-Generation Sequencing
10:18

Amplification of Near Full-length HIV-1 Proviruses for Next-Generation Sequencing

Published on: October 16, 2018

15.3K
Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection
08:15

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection

Published on: January 31, 2020

7.5K

Related Experiment Videos

Last Updated: Apr 26, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

19.2K
Amplification of Near Full-length HIV-1 Proviruses for Next-Generation Sequencing
10:18

Amplification of Near Full-length HIV-1 Proviruses for Next-Generation Sequencing

Published on: October 16, 2018

15.3K
Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection
08:15

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection

Published on: January 31, 2020

7.5K